Literature DB >> 31738606

Linking lncRNAs to regulation, pathogenesis, and diagnosis of pulmonary hypertension.

Yan Zhang1, Mianmian Wu1, Yunshan Cao2, Fang Guo1, Yahong Li1.   

Abstract

Pulmonary hypertension (PH) is a syndrome characterized by a persistent increase in pulmonary vascular resistance. Due to the lack of specificity in clinical manifestations, patients are usually diagnosed at the late stage of PH, which is hard to treat and often causes right heart failure and death. Furthermore, the regulation and pathogenesis of PH remain obscure. Recently, long noncoding RNAs (lncRNAs), a type of transcript longer than 200 nt that lacks protein-coding ability, have been found to substantially influence the incidence and progression of various diseases through regulating gene expression at the chromatin, transcriptional, post-transcriptional, translational, and even post-translational levels. The crucial roles of lncRNAs in PH have started to draw widespread attention. This review summarizes the regulatory, pathogenic, and diagnostic roles of lncRNAs in PH, in the hope to facilitate the search for early diagnostic markers of and effective therapeutic targets for this devastating disease.

Entities:  

Keywords:  Pulmonary hypertension; long noncoding RNA; pulmonary arterial smooth muscle cells; pulmonary artery endothelial cells; vascular remodeling

Year:  2019        PMID: 31738606     DOI: 10.1080/10408363.2019.1688760

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  2 in total

1.  Long Noncoding RNA TUG1 Aggravates Cerebral Ischemia/Reperfusion Injury by Acting as a ceRNA for miR-3072-3p to Target St8sia2.

Authors:  Miao Chen; Feng Wang; Limin Fan; Hairong Wang; Shuo Gu
Journal:  Oxid Med Cell Longev       Date:  2022-04-19       Impact factor: 7.310

2.  LncRNA OIP5-AS1 accelerates intervertebral disc degeneration by targeting miR-25-3p.

Authors:  Zhaoping Che; Jie Xueqin; Zongyu Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.